Lung cancer causes hyponatremia (low blood sodium) primarily because certain lung tumors produce a hormone that tricks the kidneys into retaining too much water, diluting sodium in the blood. This is especially common in small cell lung cancer, where roughly 26% of patients develop low sodium levels. Non-small cell lung cancer causes it too, though less frequently, at about 16% of patients.
How Lung Tumors Disrupt Sodium Balance
The most common reason lung cancer drives sodium levels down is a condition called SIADH, or syndrome of inappropriate antidiuretic hormone secretion. Normally, your brain releases antidiuretic hormone (ADH) when you’re dehydrated, signaling the kidneys to hold onto water. Lung cancer cells, particularly small cell lung cancer cells, can produce ADH on their own, completely independent of what your body actually needs.
This rogue hormone floods the bloodstream and tells the kidneys to keep reabsorbing water even when sodium levels are already low. The result is that your blood becomes diluted. Your total sodium may not have changed much, but there’s so much extra water in circulation that the concentration drops. The kidneys, responding to what they think is a legitimate hormonal signal, continue concentrating the urine and holding onto water they should be releasing.
Other Ways Lung Cancer Lowers Sodium
SIADH accounts for most cases, but it’s not the only mechanism at play.
Lung cancer frequently spreads to the adrenal glands, the small organs sitting on top of each kidney that produce cortisol and aldosterone. When metastases destroy more than 90% of the functional tissue in both adrenal glands, the body can no longer make enough aldosterone, the hormone responsible for telling the kidneys to retain sodium. Without it, sodium pours out in the urine. This adrenal insufficiency can be hard to recognize in cancer patients because its symptoms, including weakness, nausea, and low blood pressure, overlap with the effects of cancer itself or its treatment.
Chemotherapy drugs used for lung cancer can also contribute directly. Cisplatin and cyclophosphamide, both commonly used in lung cancer regimens, are known to cause low sodium as a side effect. Some patients end up with hyponatremia from the treatment rather than the tumor, or from both simultaneously.
Symptoms at Different Sodium Levels
The symptoms of low sodium are primarily neurological, because the brain is highly sensitive to shifts in water balance. How severe they get depends on both how low sodium drops and how quickly it falls.
Mild hyponatremia (sodium below 135 mmol/L) often produces no noticeable symptoms at all. Once levels fall below 125 to 130, nausea and a general sense of feeling unwell are typically the first signs. Below 120 to 115, things escalate to headaches, confusion, extreme drowsiness, and potentially seizures, coma, or respiratory arrest. Noncardiogenic pulmonary edema, where fluid accumulates in the lungs without a heart problem, has also been reported.
The speed of the drop matters as much as the absolute number. A gradual decline over weeks may produce surprisingly few symptoms, while a rapid drop to the same level can be life-threatening. Most lung cancer patients with hyponatremia fall into the mild to moderate range, and only a minority have symptoms at the time of diagnosis.
Why Small Cell Lung Cancer Is More Affected
Small cell lung cancer (SCLC) is a neuroendocrine tumor, meaning it arises from cells that share features with both nerve cells and hormone-producing cells. These cells are naturally inclined to produce hormones, and ADH is one of the most common ones they secrete inappropriately. This is why SIADH occurs in roughly one in four SCLC patients, compared to about one in six with non-small cell types. The connection is strong enough that an unexpected finding of low sodium sometimes leads to the initial discovery of a small cell lung tumor.
How Low Sodium Affects Prognosis
Hyponatremia in lung cancer is more than an inconvenient lab value. A large Danish study tracking 453 small cell lung cancer patients over 10 years found that those with low sodium survived roughly 50% less time than those with normal levels. Across cancer types, patients whose sodium normalized with treatment had better outcomes than those whose levels remained low. Hospital stays were also significantly longer for patients with persistent hyponatremia.
This doesn’t necessarily mean the low sodium itself shortens survival. In many cases, it signals a more aggressive or advanced cancer that is producing more ADH or has spread more extensively. When chemotherapy successfully shrinks the tumor, ADH production often drops and sodium levels recover on their own, which is why normalizing sodium tends to track with better outcomes overall.
How It’s Managed
The most important treatment for cancer-related hyponatremia is treating the cancer itself. When chemotherapy reduces tumor size, the source of excess ADH shrinks, and sodium levels often correct without any additional intervention.
For mild, chronic cases without symptoms, fluid restriction is the standard first step. By limiting how much water you take in, the kidneys can gradually let sodium concentrations rise. In practice, though, fluid restriction is often hard to maintain and not always sufficient.
When fluid restriction fails, medications that block ADH’s effect on the kidneys become an option. The most commonly used is tolvaptan, which causes the kidneys to excrete water without losing sodium. It’s started at a low dose and gradually increased over days while sodium levels are closely monitored. Importantly, patients taking tolvaptan should not restrict fluids at the same time, because the combination can cause dehydration.
Severe, rapidly developing hyponatremia with neurological symptoms like seizures or coma requires emergency treatment with concentrated saline solution to raise sodium levels in a controlled way. Correcting too quickly carries its own risk of serious brain damage, so the pace of correction is carefully managed in a hospital setting. Tolvaptan is specifically not recommended for these acute, severe cases because its effects are harder to control precisely.
Other strategies for milder cases include increasing protein or salt intake and using certain diuretics to help flush excess water when urine remains very concentrated. Any medications that might be contributing to low sodium are also reviewed and adjusted when possible.